Experienced biotechnology entrepreneurs, distinguished scientists and a development team with a track record of success
Our Commitment to Data-driven Science
First to discover
The impact of disulfiram and azlocillin on persister bacteria in Lyme disease
A narrow-spectrum, selective, anti-spirochetal compound with limited impact on healthy gut microbiome
A distinct microbiome signature for patients with late-stage Lyme disease
A therapeutic with potential to address the primary cause of advanced periodontal disease
Leadership
Mark de Souza, PhD
Co-Founder and Executive Chairman
Matthew Tindall, MBA
Co-Founder, President and Chief Executive Officer
Mark de Souza, PhD
Co-Founder and Executive Chairman
Matthew Tindall, MBA
Co-Founder, President and Chief Executive Officer
Curtis Scribner, MD, MBA
Co-Founder, Chief Medical Officer and Head of Clinical and Regulatory
James Kanter
VP, Operations and Manufacturing
Kip Vought
Regulatory Strategy
Monil Shah, PharmD, MBA
Clinical Development Strategy
Kim Lewis
Dr Charles Chiu
Monica E. Embers